Evidence map›Paper›PMID 32817629›Full record

ArticlePloS one2020

Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study.

Silvana Di Yacovo, Maria Saumoy, José Luís Sánchez-Quesada, Antonio Navarro, Dmitri Sviridov, Manuel Javaloyas, Ramon Vila, Anton Vernet, Hann Low, Judith Peñafiel and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Silvana Di YacovoHIV and STD Unit, Infectious Disease Service, Hospital Universitari de Bellvitge, Bellvitge Biomedical Research Institute, Hospitalet de Llobregat, Spain.
Maria SaumoyHIV and STD Unit, Infectious Disease Service, Hospital Universitari de Bellvitge, Bellvitge Biomedical Research Institute, Hospitalet de Llobregat, Spain.ORCID 0000-0002-0047-1991
José Luís Sánchez-QuesadaBiomedical Research Institute IIB Sant Pau, Barcelona, Spain, Biochemistry and Molecular Biology Department, Universitat Autònoma, Barcelona, Spain.
Antonio NavarroHIV and STD Unit, Infectious Disease Service, Hospital Universitari de Bellvitge, Bellvitge Biomedical Research Institute, Hospitalet de Llobregat, Spain.
Dmitri SviridovBaker Heart and Diabetes Institute, Melbourne, VIC, Australia.
Manuel JavaloyasInternal Medicine Service, Hospital de Viladecans, Viladecans, Spain.
Ramon VilaVascular Surgery Service, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain.
Anton VernetDepartment of Mechanical Engineering, Universitat Rovira i Virgili, Tarragona, Spain.ORCID 0000-0002-7028-1368
Hann LowBaker Heart and Diabetes Institute, Melbourne, VIC, Australia.
Judith PeñafielBiostatistics Unit, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain.
Benito GarcíaHIV and STD Unit, Infectious Disease Service, Hospital Universitari de Bellvitge, Bellvitge Biomedical Research Institute, Hospitalet de Llobregat, Spain.
Jordi Ordoñez-LlanosBiomedical Research Institute IIB Sant Pau, Barcelona, Spain, Biochemistry and Molecular Biology Department, Universitat Autònoma, Barcelona, Spain.
Daniel PodzamczerHIV and STD Unit, Infectious Disease Service, Hospital Universitari de Bellvitge, Bellvitge Biomedical Research Institute, Hospitalet de Llobregat, Spain.
Bellvitge University Hospital · ESBaker Heart and Diabetes Institute · AUHospital de Viladecans · ESUniversitat Rovira i Virgili · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess the effect of HIV infection and combined antiretroviral therapy (c-ART) on various proatherogenic biomarkers and lipids and to investigate their relationship with subclinical atherosclerosis in a cohort of treatment-naive HIV-infected patients.

methodsWe performed a prospective, comparative, multicenter study of 2 groups of treatment-naive HIV-infected patients (group A, CD4>500 cells/μL, not starting c-ART; and group B, CD4<500 cells/μL, starting c-ART at baseline) and a healthy control group. Laboratory analyses and carotid ultrasound were performed at baseline and at months 12 and 24. The parameters measured were low-density lipoprotein (LDL) particle phenotype, lipoprotein-associated phospholipase A2 (Lp-PLA2), interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), sCD14, sCD163, monocyte chemoattractant protein-1(MCP-1), and asymmetric dimethylarginine (ADMA). A linear mixed model based on patient clusters was used to assess differences in biomarkers between the study groups and over time.

resultsThe study population comprised 62 HIV-infected patients (group A, n = 31; group B, n = 31) and 22 controls. Age was 37 (30-43) years, and 81% were men. At baseline, the HIV-infected patients had a worse LDL particle phenotype and higher plasma concentration of sCD14, sCD163, hs-CRP, and LDL-Lp-PLA2 than the controls. At month 12, there was an increase in total cholesterol (p = 0.002), HDL-c (p = 0.003), and Apo A-I (p = 0.049) and a decrease in sCD14 (p = <0.001) and sCD163 (p<0.001), although only in group B. LDL particle size increased in group B at month 24 (p = 0.038). No changes were observed in group A or in the healthy controls. Common carotid intima-media thickness increased in HIV-infected patients at month 24 (Group A p = 0.053; group B p = 0.048). Plasma levels of sCD14, sCD163, and hs-CRP correlated with lipid values.

conclusionsIn treatment-naive HIV-infected patients, initiation of c-ART was associated with an improvement in LDL particle phenotype and inflammatory/immune biomarkers, reaching values similar to those of the controls. HIV infection was associated with progression of carotid intima-media thickness.

Indexed as

AdultAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveAtherosclerosisBiomarkersCarotid Intima-Media ThicknessCholesterolControl GroupsC-Reactive ProteinFemaleHIV InfectionsHumansInflammationLipidsLipoproteins, LDLMaleAnti-Retroviral AgentsBiomarkersCholesterolC-Reactive ProteinLipidsLipoproteins, LDL

Identifiers

PMID32817629
PMCPMC7446923
OpenAlexW3081206852

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.